Alphatec Reports Strong 2025 Results, 2026 Outlook

Alphatec Holdings announced preliminary 2025 results and a 2026 outlook on January 12, reporting full-year revenue up 25% to about $763.4–$764.4 million, a 26% rise in surgical revenue, and year-end cash of $161 million. The company projects $890 million revenue and roughly $130 million adjusted EBITDA for 2026, secured U.S. distribution rights for OsteoAdapt, and saw analysts reaffirm Buy ratings.
Scoring Rationale
Official financial update and strategic distribution deal; limited industry impact and shallow reporting reduces broader significance.
Practice with real Health & Insurance data
90 SQL & Python problems · 15 industry datasets
250 free problems · No credit card
See all Health & Insurance problems

